The facility provides pharmaceutical formulation and fill-finish development services primarily for large molecule programs, although it will have additional capacity for the development of small molecule dosage forms.
Catalent aims to complete improvements to the 180,000-square-foot facility in 2022, with work expected to begin later this year in September.
In terms of equipment, the facility will be equipped with a high speed flexible line capable of filling vials, syringes or cartridges under barrier isolator technology, as well as upgrades to analytical laboratories and of quality control.
The planned site upgrade comes as Catalent finds its services in high demand, as manufacturers seek to secure the ability to manufacture and fill finishing services for COVID-19 vaccines.
In January, the company struck a deal for Bristol’s Myers Squibb site in Anagni, Italy, and then found its services requested by AstraZeneca for the fill-finish of its potential vaccine at the same site.
In the United States, Catalent has pledged to provide large-scale commercial manufacture for Johnson & Johnson’s vaccination effort and is close to completing the refill of Moderna’s RNA vaccine, sealing deals for work with three of the main efforts against the novel coronavirus. .